Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100S9E5
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥13.7bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥7.0bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥621m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥623m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥100.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥112.1bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.3bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥68.7bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥68.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥21.5bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥2.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥341m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥42.22023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥9.832023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥40.532023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥9.462023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio68.6%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥338m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥187m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥50m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-09-30¥133m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-07-01 → 2023-09-30¥45m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥38m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥13m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-07-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-07-01 → 2023-09-30¥566m
—segment totalrevenue2023-04-01 → 2023-09-30¥13.8bn
—segment totalrevenue2023-07-01 → 2023-09-30¥7.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥13.7bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥7.0bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥89m
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥13m
—segment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 887
ItemContextValueUnit
Comprehensive income IFRSPrior1YTDDuration1442000000JPY
Comprehensive income IFRSCurrentYTDDuration2667000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration1449000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration2666000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration-7000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration0JPY
Comprehensive income IFRSPrior1YTDDuration1442000000JPY
Comprehensive income IFRSCurrentYTDDuration2667000000JPY
Profit loss IFRSPrior1QuarterDuration677000000JPY
Profit loss IFRSCurrentQuarterDuration623000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration2000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration1000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration2000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration1000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration-0JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration-0JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration-0JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration-0JPY
Other comprehensive income IFRSPrior1QuarterDuration2000000JPY
Other comprehensive income IFRSCurrentQuarterDuration0JPY
Comprehensive income IFRSPrior1QuarterDuration679000000JPY
Comprehensive income IFRSCurrentQuarterDuration624000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1QuarterDuration680000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentQuarterDuration622000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1QuarterDuration-1000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentQuarterDuration1000000JPY
Comprehensive income IFRSPrior1QuarterDuration679000000JPY
Comprehensive income IFRSCurrentQuarterDuration624000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember9091000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember12483000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-2000000JPY
Equity IFRSPrior2YearInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-4000000JPY
Equity IFRSPrior2YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Equity IFRSPrior2YearInstant_ShareAcquisitionRightsIFRSMember21000000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-1000000JPY
Other comprehensive income IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember6000000JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-1000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass